Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

504.74 -9.08 (-1.77%)

Streaming Delayed Price Updated: 1:15 PM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm

February 26, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Why United Therapeutics (UTHR) Shares Are Sliding Today

February 26, 2026

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations,...

Via StockStory

Topics Earnings

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss ↗

February 25, 2026

Via Chartmill

United Therapeutics Corp. (NASDAQ:UTHR) Passes the "Caviar Cruise" Quality Investing Screen ↗

February 12, 2026

Via Chartmill

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗

February 25, 2026

United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”

Via Stocktwits

United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates

February 25, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share...

Via StockStory

United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For

February 23, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

6 Stock Ideas for the Next 5 Years ↗

February 17, 2026

Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks!

Via The Motley Fool

Topics Artificial Intelligence

A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack

January 29, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United...

Via StockStory

Topics Artificial Intelligence

$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24% ↗

January 29, 2026

Vipshop Holdings is a major Chinese e-commerce retailer specializing in branded discount sales for value-focused consumers.

Via The Motley Fool

Topics Economy

This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding ↗

January 29, 2026

Via The Motley Fool

Topics Credit Cards ETFs

Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)

January 27, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

3 Market-Beating Stocks to Target This Week

January 15, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

Topics Credit Cards Supply Chain

Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing ↗

January 15, 2026

This specialty insurer delivers tailored property and casualty coverage for commercial and individual clients across diverse sectors.

Via The Motley Fool

Topics Bonds Regulatory Compliance

Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase ↗

January 15, 2026

This fast-casual chain pairs Mediterranean dining with grocery retail, leveraging a vertically integrated, multi-channel strategy.

Via The Motley Fool

Topics Regulatory Compliance

2 Cash-Heavy Stocks to Target This Week and 1 We Question

January 11, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

December 21, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.

Via StockStory

Topics Artificial Intelligence

Why a $27 Million Buy Signals New Confidence in Weatherford Stock ↗

December 09, 2025

One global services provider just landed a long list of new contracts — and a major fund has quietly built a sizable stake.

Via The Motley Fool

Topics Regulatory Compliance

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy? ↗

December 09, 2025

One major fund is betting that Signet’s margin rebound is just getting started.

Via The Motley Fool

Topics Regulatory Compliance

Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock ↗

December 09, 2025

One value-focused hedge fund just doubled down on one of North America’s biggest coal exporters — here’s what that could mean for the stock’s next chapter.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? ↗

December 09, 2025

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?

Via The Motley Fool

Topics Regulatory Compliance

United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗

December 05, 2025

United Therapeutics (UTHR) presents a compelling value investment case with strong profitability, a debt-free balance sheet, and a valuation discounted relative to its biotech sector peers.

Via Chartmill

United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗

November 26, 2025

United Therapeutics (UTHR) excels as a Caviar Cruise quality stock with strong growth, high profitability, a debt-free balance sheet, and exceptional returns on capital.

Via Chartmill

2 Mooning Stocks on Our Buy List and 1 That Underwhelm

November 21, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗

November 12, 2025

United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors.

Via Chartmill

3 Reasons Investors Love United Therapeutics (UTHR)

November 09, 2025

United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, reaching $448.91 per share. This performance may have investors wondering how to...

Via StockStory

Is United Therapeutics Corp Gaining or Losing Market Support? ↗

November 07, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.